Moderna, a biotechnology company based in the United States that develops messenger RNA drugs, will test two HIV mRNA vaccines in humans at the same time. Clinical trials are expected to begin before the end of 2021.
According to a publication on the NIH-operated website ClinicalTrials.gov, two experimental vaccines, Moderna mRNA-1644 and mRNA-1644v2-Core, have passed phase I testing. The randomised trial, which will be conducted in humans for the first time, will enrol approximately 56 adults between the ages of 18 and 50. Some of the volunteers have the human immunodeficiency virus. The study is expected to be completed around May 2023.
Moderna has seen strong results as a result of the success of its mRNA-1273 COVID-19 vaccine, which is expected to sell for approximately $ 20 billion this year. It has also recently started phase I/II trials of its tetravalent mRNA mRNA-1010 candidate for a seasonal influenza vaccine.
Original Story: FREE NEWS